Going into 2026, biotech company Ladder Bio is embracing a new identity.
Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...
Zacks Investment Research on MSN
ANIP vs. TEVA: Which drug stock is the better buy right now?
Both ANI Pharmaceuticals ANIP and Teva Pharmaceuticals TEVA operate in the pharmaceutical sector, focusing on generic and ...
AbbVie has signed a landmark US administration deal, pledging $100bn in domestic manufacturing and R&D investment in exchange ...
AbbVie is the 16th of 17 pharmaceutical giants to agree a cut-price medicines deal in the US, adding a US$100bn investment ...
AbbVie Inc.’s founding CEO Richard Gonzalez will step down July 1, the drugmaker said Tuesday, and will be replaced by the company’s current president and chief operating officer, Robert Michael.
ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ...
ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million -- KPL-38 ...
Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...
As prescription drug prices in the US continue to rise, political leaders across administrations, including recently US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback